Sign in

Neurophysiology & Synapses

Usually weeks 3-4 of a medical physiology course, once membrane potentials are built

Once the action potential exists, the course asks what happens when it arrives somewhere: the synapse. The chemical synapse is the exam's home turf because nearly every neurologic and psychiatric drug — and several famous toxins — acts on one of its five steps. Learn the neuromuscular junction as the model synapse first (it's the one with a disease for every step), then generalize: EPSPs and IPSPs are just graded potentials with names, summation is the arithmetic the axon hillock performs, and the transmitter systems are a short table that pays rent for the rest of PA school.

On the PANCE this unit feeds:Neurology · 7%Musculoskeletal · 8%

This guide is the frame. The exams are written from your lectures— drop this unit's slides on the dashboard to get flashcards and board-style questions from your own course, and quiz them all semester (a course whose exams re-test earlier units rewards nothing more than early, repeated self-testing). The physiology playbook has the weekly loop.

Drop a lecture

Free30 study kits/mo · 1 diagram deck · 1 board-graded quiz · 2 tutor Qs/wk

Pro $20/mono monthly cap (5 kits/day) · 10 diagram decks · See plans →

AI-authored study notes, not faculty-reviewed and not medical advice. Verify every mechanism against your course materials and faculty; programs differ in emphasis.

High-Yield Pearl

File every synaptic drug, toxin, and disease under one of the five steps of transmission — arrival, Ca2+ entry, vesicle fusion, receptor binding, termination — and most neuro-pharm questions become a lookup instead of a memory feat.

What the exam asks
Mechanisms, curves, and what happens when each one fails.
  • The chemical synapse in five steps. (1) The AP invades the presynaptic terminal; (2) voltage-gated Ca2+ channels open, and Ca2+ entry is the trigger — transmitter release scales steeply with it; (3) synaptic vesicles fuse via the SNARE apparatus and release transmitter; (4) transmitter diffuses across the cleft and binds postsynaptic receptors — ionotropic (a channel opens in milliseconds) or metabotropic (a G-protein cascade, slower and longer-lasting); (5) the signal is TERMINATED by reuptake, enzymatic degradation, or diffusion. Nearly every synaptic drug and toxin maps to exactly one of these steps — file each new agent by its step.
  • Electrical synapses exist and are the exception. Gap junctions couple cells directly — bidirectional, essentially no delay, no transmitter. In humans they matter in cardiac muscle, single-unit smooth muscle, and some brain circuits. The chemical synapse's ~0.5 ms delay (Ca2+ entry and vesicle fusion) is the price paid for amplification, one-way traffic, and the ability to be excitatory, inhibitory, or modulated — which is why it's the rule and gap junctions the exception.
  • EPSPs and IPSPs. An EPSP is a graded DEPOLARIZATION — the transmitter opened channels pulling Vm toward a potential above threshold (classically non-selective cation channels, as at nicotinic and glutamate receptors). An IPSP is a graded hyperpolarization or clamping — Cl− channels (GABA-A, glycine) or K+ channels (GABA-B, via G proteins) pulling Vm toward ECl or EK. Note the subtlety the exam enjoys: with ECl ≈ −70, opening Cl− channels may not move a resting cell at all, yet still inhibits it by shunting — holding Vm near −70 against every EPSP's effort.
  • Summation — the neuron's arithmetic. One EPSP almost never reaches threshold. TEMPORAL summation: the same input fires repeatedly, each EPSP arriving before the last decays. SPATIAL summation: different inputs arrive together and add. The axon hillock (initial segment) integrates them — it has the highest voltage-gated Na+ channel density and thus the lowest threshold, so IT decides whether the neuron fires. Inputs synapsing close to the hillock outvote distal dendritic ones, because graded potentials decay with distance.
  • The neuromuscular junction — the model synapse. One motor axon, one muscle fiber, one transmitter (ACh), one receptor (nicotinic, ionotropic), and — uniquely — a safety factor so large that every motor-nerve AP normally triggers a muscle AP: the end-plate potential is far suprathreshold. ACh is terminated by acetylcholinesterase in the cleft (not reuptake of ACh itself; choline is recycled). Because transmission is obligatory here, ANY pharmacologic or immune interference shows up as weakness — which is why the NMJ has a named disease or drug for every synaptic step.
  • The NMJ's disease-per-step map. Presynaptic Ca2+ channels: Lambert-Eaton syndrome (antibodies; weakness that IMPROVES with repeated use as Ca2+ accumulates; paraneoplastic with small cell lung cancer). Vesicle fusion: botulinum toxin cleaves SNAREs (descending flaccid paralysis; also the cosmetic and therapeutic agent). Postsynaptic receptor: myasthenia gravis (antibodies deplete nicotinic receptors; fatigable weakness, worse with use — ptosis and diplopia by evening). Degradation: cholinesterase inhibitors (neostigmine, pyridostigmine) raise cleft ACh — the myasthenia treatment; organophosphates do it irreversibly — the poisoning. Receptor blockade: curare-type neuromuscular blockers used in anesthesia.
  • The transmitter table worth owning. Glutamate — the CNS's main excitatory transmitter (AMPA fast, NMDA the coincidence-detecting, Ca2+-passing, Mg2+-plugged receptor behind synaptic plasticity and excitotoxicity). GABA (brain) and glycine (cord) — the main inhibitors, via Cl−; benzodiazepines, barbiturates, and alcohol potentiate GABA-A. ACh — NMJ, all autonomic ganglia, parasympathetic targets, and attention/memory circuits (Alzheimer target). The monoamines, each from a nameable nucleus: dopamine (substantia nigra/VTA — movement, reward; Parkinson, antipsychotics), norepinephrine (locus ceruleus — arousal; sympathetic postganglionics), serotonin (raphe — mood, sleep; SSRIs). Learn each as transmitter → receptor family → terminator → one drug and one disease.
  • Termination decides the drug list. ACh is degraded in the cleft (acetylcholinesterase — hence cholinesterase inhibitors); the monoamines are RECAPTURED (reuptake transporters — hence SSRIs, SNRIs, cocaine's mechanism at the dopamine transporter) and mopped up by MAO/COMT (hence MAO inhibitors); glutamate is cleared largely by astrocytes (the glutamate-glutamine cycle — its failure contributes to excitotoxic injury in stroke). If you know how a transmitter's action ends, you can usually derive the drug class that prolongs it.
  • Plasticity — why repetition is not a slogan. Synaptic strength is adjustable: brief high-frequency use potentiates some synapses for the long term (LTP — NMDA receptors admit Ca2+ only when the postsynaptic cell is already depolarized, a molecular AND-gate), and low-frequency use depresses others (LTD). This is the accepted cellular substrate of learning and the physiologic argument for spaced active recall over rereading. It also has a dark side: too much glutamate signaling kills neurons (excitotoxicity).
Worth drilling · 27 concepts
Each with the one fact that identifies it. Your course's slides are the authority; use this to check your list against.
  1. 1Voltage-gated Ca2+ channel (presynaptic) — its Ca2+ entry is the trigger for transmitter release
  2. 2SNARE proteins — dock and fuse synaptic vesicles; cleaved by botulinum toxin
  3. 3Ionotropic receptor — transmitter-gated ion channel; milliseconds fast (nicotinic, GABA-A, AMPA)
  4. 4Metabotropic receptor — G-protein-coupled; slower, longer-lasting (muscarinic, GABA-B)
  5. 5Synaptic delay — ~0.5 ms for Ca2+ entry and vesicle fusion; absent at gap junctions
  6. 6EPSP — graded depolarization toward threshold; classically a non-selective cation channel opening
  7. 7IPSP — graded hyperpolarization or shunting via Cl− or K+ channels
  8. 8Shunting inhibition — open Cl− channels clamp Vm near ECl even without visibly hyperpolarizing
  9. 9Temporal summation — one input firing rapidly; EPSPs stack before decaying
  10. 10Spatial summation — simultaneous inputs from different synapses add together
  11. 11Axon hillock — lowest-threshold zone, densest Na+ channels; the neuron's decision point
  12. 12End-plate potential — the NMJ's giant EPSP; normally always suprathreshold (the safety factor)
  13. 13Nicotinic ACh receptor — ionotropic cation channel at the NMJ and all autonomic ganglia
  14. 14Acetylcholinesterase — terminates ACh in the cleft; the myasthenia-treatment and organophosphate target
  15. 15Myasthenia gravis — antibodies deplete postsynaptic nicotinic receptors; fatigable weakness, worse with use
  16. 16Lambert-Eaton syndrome — antibodies against presynaptic Ca2+ channels; weakness that improves with use
  17. 17Botulinum toxin — cleaves SNAREs, blocking vesicle release; descending flaccid paralysis
  18. 18Tetanus toxin — blocks transmitter release from INHIBITORY interneurons; spastic paralysis
  19. 19Glutamate — the CNS's main excitatory transmitter; AMPA and NMDA receptors
  20. 20NMDA receptor — Mg2+-plugged, Ca2+-passing coincidence detector; plasticity and excitotoxicity
  21. 21GABA — the brain's main inhibitory transmitter; benzodiazepines potentiate GABA-A
  22. 22Glycine — the spinal cord's inhibitory transmitter; blocked by strychnine
  23. 23Dopamine — substantia nigra and VTA; movement and reward; Parkinson's missing transmitter
  24. 24Norepinephrine — locus ceruleus and sympathetic postganglionics; arousal and vigilance
  25. 25Serotonin — raphe nuclei; mood and sleep; the SSRI target
  26. 26Reuptake transporter — ends monoamine signaling; the SSRI/SNRI and cocaine site
  27. 27Long-term potentiation — high-frequency use strengthens a synapse via NMDA-admitted Ca2+
Practice it
Active recall over the drill list — flip and claim, match the pairs, produce the answers cold, fill in the diagram, or read the curves like the exam does.

Every concept on the drill list, one card at a time — the name up front, the fact that identifies it on the flip. Claim each card honestly and the deck learns what to lead with next time. Progress lives in this browser only.

What everyone misses
The distinctions that lose points on this material, year after year.
  • Myasthenia vs Lambert-Eaton — which side of the cleft, which direction with use. Both are autoimmune NMJ weakness; the exam separates them on two hinges. Myasthenia is POSTsynaptic (receptors) and fatigues WITH use — receptors are scarce, so repeated stimulation runs the response down (evening ptosis). Lambert-Eaton is PREsynaptic (Ca2+ channels) and IMPROVES with use — repetitive firing accumulates terminal Ca2+, squeezing out more ACh (and it travels with small cell lung cancer). Swap either axis and you've picked the distractor.
  • Botulinum and tetanus toxins both cleave SNAREs — and produce opposite pictures. The mechanism is shared; the TARGET NEURON differs. Botulinum acts at the NMJ and cholinergic terminals: no release, FLACCID paralysis. Tetanus toxin travels retrograde to spinal inhibitory interneurons and silences the inhibition of motor neurons: unopposed firing, SPASTIC paralysis — trismus and opisthotonus. 'Same molecule class, opposite disease' is precisely why examiners love the pair.
  • An IPSP doesn't have to hyperpolarize to inhibit. With ECl sitting near the resting potential, opening GABA-A channels may move Vm barely at all — students conclude 'no effect.' Wrong: the open Cl− conductance shunts depolarizing current, so concurrent EPSPs shrink and threshold is never reached. Inhibition is about pulling Vm toward (and anchoring it at) a sub-threshold potential — not about the direction of the initial deflection.
  • The end-plate potential is not an action potential. The EPP is a graded potential — decremental, produced by ligand-gated (not voltage-gated) channels, confined to the end plate. It normally TRIGGERS a muscle AP because the safety factor makes it hugely suprathreshold — which is exactly what myasthenia erodes. Questions that show a 'reduced but present end-plate response with no muscle contraction' are testing whether you keep the two events separate.
  • Ionotropic vs metabotropic is a speed-and-duration axis, not an importance axis. Students rank 'direct channel' receptors as the real ones and G-protein receptors as minor. The autonomic nervous system runs almost entirely on metabotropic receptors (every muscarinic and adrenergic receptor), as do most psychiatric drug targets. Sort receptors by time course — milliseconds/ionotropic vs hundreds of milliseconds-to-minutes/metabotropic — and expect a vignette clue about speed or persistence.
  • More transmitter is not always more signal. Organophosphate poisoning floods the cleft with ACh — and after initial overactivity, the depolarized end plate INACTIVATES its Na+ channels and receptors desensitize: depolarizing blockade, weakness, respiratory failure. The same logic runs succinylcholine's paralysis. It's the synaptic rerun of the hyperkalemia paradox: sustained depolarization silences excitable tissue.
Clinical correlations
Where this unit shows up again — in clinic, on rotations, and on the boards.
  • Myasthenia gravis at the bedside. Fatigable ptosis and diplopia worse through the day, improving with rest or ice; diagnosed with receptor antibodies and decremental response on repetitive nerve stimulation; treated with pyridostigmine (more cleft ACh) and immunotherapy. Watch for myasthenic crisis with respiratory weakness — the NMJ's safety factor, gone.
  • Organophosphate poisoning. An agricultural exposure with salivation, lacrimation, urination, defecation, bronchorrhea, miosis, bradycardia — then muscle fasciculations giving way to weakness: irreversible cholinesterase inhibition flooding every cholinergic synapse. Atropine blocks the muscarinic storm; pralidoxime rescues the enzyme before it 'ages.' The vignette is a tour of everywhere ACh acts.
  • Botulism vs tetanus, clinically. Botulism: canned food or an infant's honey, descending flaccid paralysis starting with cranial nerves (diplopia, dysphagia), afebrile, pupils often dilated. Tetanus: a puncture wound, then trismus, risus sardonicus, and painful extensor spasms. Both are SNARE-cleaving clostridial toxins; the target neuron writes the opposite exams.
  • Benzodiazepines, barbiturates, and alcohol share a receptor. All three potentiate GABA-A Cl− current (benzodiazepines increase opening FREQUENCY, barbiturates opening DURATION — a classic discriminator), which is why they cross-react: alcohol withdrawal is treated with benzodiazepines, and combining the classes depresses respiration synergistically. Flumazenil antagonizes the benzodiazepine site specifically.
  • Parkinson disease as a transmitter deficit. Degeneration of substantia nigra dopamine neurons — bradykinesia, rigidity, resting tremor. Treatment logic is pure synaptic physiology: replace precursor (levodopa, with carbidopa to keep decarboxylation out of the periphery), stimulate the receptor (agonists), or block the degraders (MAO-B, COMT inhibitors). Antipsychotics run the same synapse in reverse — dopamine blockade producing parkinsonism.
  • SSRIs and the reuptake principle. Blocking the serotonin transporter prolongs serotonin's synaptic dwell time — the first-line pharmacology of depression and anxiety. The delayed onset (weeks) is itself a synaptic lesson: the benefit tracks receptor-level and plasticity adaptations, not the immediate transmitter rise. Cocaine applies the same mechanism to the dopamine transporter, with a different clinical story.
  • Stroke and excitotoxicity. Ischemic neurons depolarize, dump glutamate, and fail to recapture it; NMDA receptors flood downstream cells with Ca2+, activating destructive enzymes — the penumbra's mode of death and the reason 'time is brain.' The same overactivation in miniature underlies the theory behind memantine (an NMDA blocker) in Alzheimer disease.

Frequently asked

← Membrane PotentialsAll units →